He made the disclosure on Thursday during a press briefing on the Marburg outbreak, co-hosted by the Africa Centres for Disease Control and Prevention (Africa CDC).
'We expect around 5,000 doses of Remdesivir for emergency treatment of patients that are highly in need,' he said.
Rwanda confirmed its first-ever Marburg virus outbreak on September 27.
Reports show that five people have recovered, 11 have died, and 21 others are still receiving medical care.
In addition to receiving antiviral treatment, Dr. Nsanzimana highlighted ongoing discussions with several organizations to accelerate the development and distribution of a Marburg vaccine, which could be available in Rwanda in the near future.
Rwandan health authorities are working diligently to contain the spread of the virus.
Africa CDC Director General, Dr. Jean Kaseya, reassured travelers that the situation is under control.
"We are flying to Rwanda. I will be in Rwanda, attending meetings. It's an outbreak that is managed and, as we have outbreaks in all other countries, there is no travel ban. And I repeat it: travellers should not cancel their trips to Rwanda," Kaseya emphasized.
The Africa CDC has confirmed that it will send specialists to Rwanda next week to support the country's efforts in managing the outbreak.
Health officials note that individuals infected with Marburg may remain asymptomatic for three to 21 days, although some cases develop symptoms sooner.
Initial symptoms include high fever, severe headaches, muscle and joint pain, and fatigue, followed by gastrointestinal symptoms like nausea and vomiting. As the disease progresses, the condition worsens as the body deteriorates.
To prevent infection, health experts recommend maintaining strict hygiene practices and avoiding the sharing of personal items with individuals exhibiting Marburg-like symptoms.
IGIHE
